JP7791083B2 - カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法 - Google Patents

カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法

Info

Publication number
JP7791083B2
JP7791083B2 JP2022520291A JP2022520291A JP7791083B2 JP 7791083 B2 JP7791083 B2 JP 7791083B2 JP 2022520291 A JP2022520291 A JP 2022520291A JP 2022520291 A JP2022520291 A JP 2022520291A JP 7791083 B2 JP7791083 B2 JP 7791083B2
Authority
JP
Japan
Prior art keywords
salt
rilpivirine
cabotegravir
administered
intramuscular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550828A (ja
JP2022550828A5 (enExample
Inventor
ヘルタ、マリア、ルドビカ、クラウウェルズ
スーザン、エル．フォード
デイビッド、アンドリュー、マーゴリス
ステファーン、ルイ、エフ．ロセーヌ
ウィリアム、ロバート、スプリーン
ロディカ、ミハエラ、ファン、ゾーリンゲン－リステア
ピーター、エバン、オーウェン、ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Publication of JP2022550828A publication Critical patent/JP2022550828A/ja
Publication of JP2022550828A5 publication Critical patent/JP2022550828A5/ja
Application granted granted Critical
Publication of JP7791083B2 publication Critical patent/JP7791083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520291A 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法 Active JP7791083B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US62/908,882 2019-10-01
US62/908,995 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (3)

Publication Number Publication Date
JP2022550828A JP2022550828A (ja) 2022-12-05
JP2022550828A5 JP2022550828A5 (enExample) 2023-10-12
JP7791083B2 true JP7791083B2 (ja) 2025-12-23

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520291A Active JP7791083B2 (ja) 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法

Country Status (11)

Country Link
US (3) US20220347174A1 (enExample)
EP (1) EP4037661A1 (enExample)
JP (1) JP7791083B2 (enExample)
KR (1) KR20220074880A (enExample)
CN (2) CN114502166A (enExample)
AU (1) AU2020358156B2 (enExample)
CA (1) CA3155587A1 (enExample)
CL (1) CL2022000790A1 (enExample)
IL (1) IL290716A (enExample)
MX (1) MX2022003945A (enExample)
WO (1) WO2021064618A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
TW202408526A (zh) * 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
KR101811314B1 (ko) * 2009-09-22 2017-12-26 얀센 알 앤드 디 아일랜드 Ｈｉｖ 감염의 치료 및 예방
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EA201790495A1 (ru) 2014-09-26 2017-09-29 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed，2019年01月，インターネット＜URL：https://cdn.clinicaltrials.gov/large-docs/52/NCT02951052/Prot_000.pdf＞
Clinical Pharmacology in Drug Development，2019年2月, Vol.8, No.5，pp.664-673
Current Opinion in HIV and AIDS，2013年, Vol.8, No.6，pp.565-571
HIV/AIDS - Research and Palliative Care，2019年7月, Vol.2019, No.11，pp.179-192
Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy，2019年02月，インターネット＜URL：https://www.croiconference.org/wp-content/uploads/sites/2/posters/2017/442_Margolis.pdf＞
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine FromCurrent Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults，2019年07月，インターネット＜URL：https://clinicaltrials.gov/study/NCT02951052?term=NCT02951052&rank=1&tab=history&a=52＞
The LANCET，2017年，Vol.390，p.1499-1510

Also Published As

Publication number Publication date
CL2022000790A1 (es) 2022-11-25
AU2020358156B2 (en) 2024-06-06
IL290716A (en) 2022-04-01
EP4037661A1 (en) 2022-08-10
CN118416069A (zh) 2024-08-02
WO2021064618A1 (en) 2021-04-08
JP2022550828A (ja) 2022-12-05
US12636285B2 (en) 2026-05-26
US12636286B2 (en) 2026-05-26
CN114502166A (zh) 2022-05-13
US20220347174A1 (en) 2022-11-03
CA3155587A1 (en) 2021-04-08
AU2020358156A1 (en) 2022-04-21
US20250302829A1 (en) 2025-10-02
US20250302830A1 (en) 2025-10-02
MX2022003945A (es) 2022-04-25
KR20220074880A (ko) 2022-06-03

Similar Documents

Publication Publication Date Title
US20250302830A1 (en) Method for treating hiv with cabotegravir and rilpivirine
US11123329B1 (en) Use of angiotensin II type 2 receptor agonist
JP2025111701A (ja) 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
Tseng et al. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
Yu et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
JP2023123523A (ja) Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物
AU2018304591A1 (en) Regimens for treating hiv infections and aids
AU2024318637A1 (en) Obefazimod for treatment of ulcerative colitis
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Raines et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
Koren et al. Scientific basis of antiretroviral therapy
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
JP2025001026A (ja) ドルテグラビル及びラミブジンでｈｉｖを治療する方法
Vanangamudi et al. Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
CA3268726A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
Flamm Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
Blonk et al. and David M. Burger
Benzer et al. The current state of HIV therapy.
ULC et al. Pr MYLAN-ATAZANAVIR
Cockroft-Gault AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Tenofovir disoproxil fumarate/Emtricitabine/Elvitegravir/Cobicistat Proprietary Product Name: Stribild Sponsor: Gilead Sciences Pty Ltd
TW201726133A (zh) Ｈｉｖ成熟抑制劑調配物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211

R150 Certificate of patent or registration of utility model

Ref document number: 7791083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150